Toronto, Canada
ProteinQure, founded in 2017 and headquartered in Canada, is at the forefront of biotechnology. Armed with the slogan "dare to deliver," the company is pioneering an AI platform designed for peptide drug design, particularly targeting extracellular targets.
Their flagship program, PQ203, is currently undergoing Phase I trials in the U.S. and Canada, addressing TOP1-resistant triple-negative breast cancer, a condition that currently lacks approved treatments. This marks a significant milestone in therapeutic advancement.
ProteinQure's platform has been rigorously validated through collaborations with four of the world's top 25 pharmaceutical companies. It leverages cutting-edge physics-based methods to explore an extensive chemical space, boasting scaffold diversity and over 3,500 non-canonical building blocks.
Recently, the company secured a $1.80M grant investment from FedDev on 01 May 2026, showcasing confidence in ProteinQure's potential. This investment bolsters their internal programs, specifically those enhancing tissue-specific payload delivery.
Ashvattha Therapeutics, Inc.
DALI Medical Devices Ltd.